CORBUS PHARMACEUTICALS

corbus-pharmaceuticals-logo

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum i... s currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

#SimilarOrganizations #People #Financial #Event #Website #More

CORBUS PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Clinical Trials Pharmaceutical

Founded:
2009-01-01

Address:
Norwood, Massachusetts, United States

Country:
United States

Website Url:
http://www.corbuspharma.com

Total Employee:
51+

Status:
Active

Contact:
(617) 963-0100

Email Addresses:
[email protected]

Total Funding:
196.95 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving


Similar Organizations

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.

Current Employees Featured

rachael-brake_image

Rachael Brake
Rachael Brake Chief Scientific Officer @ Corbus Pharmaceuticals
Chief Scientific Officer
2021-12-01

robert-discordia_image

Robert Discordia
Robert Discordia COO @ Corbus Pharmaceuticals
COO
2019-08-01

yuval-cohen_image

Yuval Cohen
Yuval Cohen Chief Executive Officer @ Corbus Pharmaceuticals
Chief Executive Officer
2013-07-01

barbara-white_image

Barbara White
Barbara White Chief Medical Officer & Head of Researchv @ Corbus Pharmaceuticals
Chief Medical Officer & Head of Researchv

ed-karski_image

Ed Karski
Ed Karski Global Head, Procurement @ Corbus Pharmaceuticals
Global Head, Procurement
2019-02-01

sean-moran_image

Sean Moran
Sean Moran CFO @ Corbus Pharmaceuticals
CFO
2014-01-01

craig-millian_image

Craig Millian
Craig Millian Chief Operating Officer @ Corbus Pharmaceuticals
Chief Operating Officer
2021-09-01

Founder


bruce-montgomery_image

Bruce Montgomery

jonathan-mow_image

Jonathan Mow

Stock Details


Company's stock symbol is NASDAQ:CRBP

Investors List

dafna-capital-management_image

Dafna Capital Management

Dafna Capital Management investment in Post-IPO Equity - Corbus Pharmaceuticals

ghost-tree-capital-group_image

Ghost Tree Capital Group

Ghost Tree Capital Group investment in Post-IPO Equity - Corbus Pharmaceuticals

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Post-IPO Equity - Corbus Pharmaceuticals

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Grant - Corbus Pharmaceuticals

fort-point-angels_image

Fort Point Angels

Fort Point Angels investment in Venture Round - Corbus Pharmaceuticals

oleg-uritsky_image

Oleg Uritsky

Oleg Uritsky investment in Venture Round - Corbus Pharmaceuticals

sternaegis-ventures_image

SternAegis

SternAegis investment in Venture Round - Corbus Pharmaceuticals

boston-harbor-angels_image

Boston Harbor Angels

Boston Harbor Angels investment in Angel Round - Corbus Pharmaceuticals

Official Site Inspections

http://www.corbuspharma.com Semrush global rank: 9.44 M Semrush visits lastest month: 157

  • Host name: ec2-34-226-46-235.compute-1.amazonaws.com
  • IP address: 34.226.46.235
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Corbus Pharmaceuticals"

Overview : Corbus Pharmaceuticals Holdings, Inc.

Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013.See details»

Corbus Pharmaceuticals - LinkedIn

Corbus Pharmaceuticals | 16,274 followers on LinkedIn. Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines | Corbus is a precision โ€ฆSee details»

Corbus Pharmaceuticals - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number (617) 963-0100 Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the โ€ฆSee details»

Corbus Pharmaceuticals - Craft

Oct 29, 2024 Corbus Pharmaceuticals has 5 employees at their 1 location and $881.71 k in annual revenue in FY 2021. See insights on Corbus Pharmaceuticals including office โ€ฆSee details»

Corbus Pharmaceuticals Company Profile | Management and

SQL International Organization for Standardization . Python Python Software Foundation . Other Communication and Collaboration Software (3 Technologies) ... [email protected]: โ€ฆSee details»

Leadership Team & Board of Directors

Ms. Jacques is the former President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (โ€œAkariโ€), a late-stage biopharmaceutical company focused on innovative โ€ฆSee details»

Corbus Pharmaceuticals Holdings Inc, 3371:STU profile - FT.com

May 12, 2025 Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness โ€ฆSee details»

Working at Corbus Pharmaceuticals - Zippia

Mar 14, 2024 www.corbuspharma.com. Organization Type. Public. CEO. Yuval Cohen. Social Media. Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical โ€ฆSee details»

Profile : Corbus Pharmaceuticals Holdings, Inc.

Address: 500 River Ridge Drive Norwood, MA 02062 US. Telephone: 617.963.0100. Fax: 617.663.6085. Email: [email protected]See details»

Corbus Pharmaceuticals Company Overview, Contact Details

Jan 31, 2024 [email protected]: 22%. [email protected]: [email protected]: 2%. [email protected]: [email protected]: 1%. โ€ฆSee details»

Corbus Pharma - 2025 Company Profile - Tracxn

6 days ago Corbus Pharma has raised a total funding of $10.4M over 5 rounds. Its first funding round was on Sep 17, 2012. Its latest funding round was a Grant (prize money) round on Jan โ€ฆSee details»

Our Company : Corbus Pharmaceuticals Holdings, Inc.

Our Company We are focused on connecting innovation to purpose. Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative โ€ฆSee details»

Corbus Pharmaceuticals Names Industry Veteran Rachelle

9 hours ago NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on โ€ฆSee details»

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End โ€ฆ

Mar 12, 2024 [email protected]. Bruce Mackle Managing Director LifeSci Advisors, LLC [email protected] to follow---Corbus Pharmaceuticals โ€ฆSee details»

About Corbus Pharmaceuticals Holdings

Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the โ€ฆSee details»

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results โ€ฆ

Mar 11, 2025 Financial Results for the Quarter and Year Ended December 31, 2024: The Company reported a net loss of approximately $9.5 million, or a net loss per diluted share of โ€ฆSee details»

Working Here : Corbus Pharmaceuticals Holdings, Inc.

Own compassion. Who are we looking for? Barrier breakers.You have grit and resilience because good medicine and strong science is worth fighting for. What we can offer?See details»

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques โ€ฆ

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today โ€ฆSee details»

Corbus Pharmaceuticals Reports Third Quarter 2021 Financial โ€ฆ

Nov 12, 2021 Corbus' current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of โ€ฆSee details»

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial โ€ฆ

Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFฮฒ and small molecules that activate or inhibit the endocannabinoid system. Corbus is โ€ฆSee details»

linkstock.net © 2022. All rights reserved